home / stock / mxct / mxct news

MXCT News and Press, MaxCyte Inc. From 05/07/24

Stock Information
Company Name: MaxCyte Inc.
Stock Symbol: MXCT
Market: NASDAQ
Website: maxcyte.com
Menu
MXCT MXCT Quote MXCT Short MXCT News MXCT Articles MXCT Message Board
Get MXCT Alerts

News, Short Squeeze, Breakout and More Instantly...
MXCT - Expected US Company Earnings on Tuesday, May 7th, 2024

Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...
MXCT - MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024

ROCKVILLE, Md., April 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioproc...

MXCT - MaxCyte signs strategic platform license with Be Biopharma

2024-04-02 08:37:14 ET More on MaxCyte MaxCyte, Inc. (MXCT) Q4 2023 Earnings Call Transcript MaxCyte says Q4 revenue is expected to be between $15.5M and $15.7M Seeking Alpha’s Quant Rating on MaxCyte Historical earnings data for MaxCyte Financ...

MXCT - MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovat...
MXCT - MaxCyte, Inc. (MXCT) Q4 2023 Earnings Call Transcript

2024-03-12 22:40:19 ET MaxCyte, Inc. (MXCT) Q4 2023 Earnings Conference Call March 12, 2024 16:30 ET Company Participants Sean Menarguez - Head of Investor Relations Maher Masoud - President & Chief Executive Officer Douglas Swirsky - Chief Financial Officer ...

MXCT - MaxCyte GAAP EPS of -$0.05 beats by $0.02, revenue of $15.67M beats by $0.61M

2024-03-12 16:12:33 ET More on MaxCyte MaxCyte says Q4 revenue is expected to be between $15.5M and $15.7M Seeking Alpha’s Quant Rating on MaxCyte Historical earnings data for MaxCyte Financial information for MaxCyte Read the full article on...

MXCT - MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

ROCKVILLE, Md., March 12, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and innovative biopro...
MXCT - Expected US Company Earnings on Tuesday, March 12th, 2024

Koninklijke KPN NV (KKPNF) is expected to report for Q4 2023 ECA Marcellus Trust I Unit (ECTM) is expected to report for Q4 2023 San Juan Basin Royalty Trust (SJT) is expected to report for Q4 2023 Avenir Wellness Solutions Inc (AVRW) is expected to report for Q4 2023 Carmell Corp...

MXCT - MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results

ROCKVILLE, Md., March 04, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioproc...

MXCT - MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences

ROCKVILLE, Md., Feb. 09, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioproce...
Previous 10 Next 10